✦ LIBER ✦

QUALITY OF LIFE ASSESSMENT IN THE RANDOMIZED PROTECT AF TRIAL OF PATIENTS AT RISK FOR STROKE WITH NON-VALVULAR ATRIAL FIBRILLATION

✍ Scribed by David R. Holmes; Vivek Reddy; Zoltan Turi; Shephal Doshi; Horst Sievert; Maurice Buchbinder; Christopher Mullin; Peter Sick

Book ID: 118582053
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 123 KB
Volume: 59
Category: Article
ISSN: 1558-3597
DOI: 10.1016/s0735-1097(12)60241-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Percutaneous Left Atrial Appendage Closu

Percutaneous Left Atrial Appendage Closure for Stroke Prophylaxis in Patients With Atrial Fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) Trial

✍ Reddy, V. Y.; Doshi, S. K.; Sievert, H.; Buchbinder, M.; Neuzil, P.; Huber, K.; 📂 Article 📅 2013 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 778 KB

Lessons learned from the AFFIRM trial—tr

Lessons learned from the AFFIRM trial—treatment of patients with atrial fibrillation at risk for stroke

✍ Albert L Waldo 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 86 KB

PCV60 Cost-Effectiveness of Dabigatran f

PCV60 Cost-Effectiveness of Dabigatran for the Prevention of Stroke in Patients with Non-Valvular Atrial Fibrillation in Australia

✍ D. Tilden; P. Germanos; J. Gordon; L. Tocchini; B. Monz 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

The Clinical Impact of Incomplete Left A

The Clinical Impact of Incomplete Left Atrial Appendage Closure With the Watchman Device in Patients With Atrial Fibrillation: A PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) Substudy

✍ Juan F. Viles-Gonzalez; Saibal Kar; Pamela Douglas; Srinivas Dukkipati; Ted Feld 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 726 KB

Antithrombotic treatment for the primary

Antithrombotic treatment for the primary prevention of stroke in patients with non valvular atrial fibrillation: A reappraisal of the evidence and network meta analysis

✍ Andrew Owen 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 552 KB

For people with non-valvular atrial fibr

For people with non-valvular atrial fibrillation rivaroxaban is non-inferior to warfarin for preventing stroke or embolism, with no difference in the risk of clinically relevant bleeding

✍ Sherwood, M.; Piccini, J. P. 📂 Article 📅 2012 🏛 BMJ Publishing Group 🌐 English ⚖ 68 KB